ACCPL vs SUDEEPPHRM: Stock Comparison
SUDEEP PHARMA is the larger company by market capitalisation. SUDEEP PHARMA shows a higher ROE, a higher dividend yield and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
ACCPL leads 3; SUDEEPPHRM leads 6 of 11
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Price
| Metric | ACCPL | SUDEEPPHRM |
|---|---|---|
| Live Price | — | ₹1,197.1 |
| Day Change | — | 4.64% |
| Volume | — | 3.08 L |
| 52-Week High | — | ₹1,378 |
| 52-Week Low | — | ₹524.05 |
| Distance from 52W High | — | -13.13% |
Valuation
| Metric | ACCPL | SUDEEPPHRM |
|---|---|---|
| Market Cap | ₹239 Cr | ₹13,549 Cr |
| P/E Ratio | — | 70.53x |
| P/B Ratio | — | 14.6x |
| EPS | ₹8.7 | ₹3.59 |
| Book Value | ₹49.22 | ₹79.51 |
| Dividend Yield | 0% | 0.13% |
Growth
| Metric | ACCPL | SUDEEPPHRM |
|---|---|---|
| Revenue Growth (TTM YoY) | 0% | 0% |
| EPS Growth (TTM YoY) | 0% | 0% |
| Qtr Sales Growth | 104.93% | 49.76% |
| Qtr Profit Growth | 103.43% | 19.98% |
Profitability & Leverage
| Metric | ACCPL | SUDEEPPHRM |
|---|---|---|
| ROE | 17.67% | 21.62% |
| ROCE | 16.34% | 19.78% |
| Net Margin | 0% | 27.14% |
| Operating Margin | 15.54% | 35.72% |
| Debt to Equity | 0.23x | 0.17x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | ACCPL | SUDEEPPHRM |
|---|---|---|
| Promoter Holding | 73.52% | 76.15% |
| FII Holding | 0% | 1.81%▲ 0.26 pp |
| DII Holding | 2.76%▲ 2.76 pp | 15.65%▼ 2.46 pp |
| Public Holding | 23.72%▼ 2.76 pp | 6.39%▲ 2.21 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: ACCPL and SUDEEP PHARMA.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.